John Stendahl, MD, PhD
Assistant Professor of Medicine (Cardiovascular Medicine)Cards
About
Research
Publications
2026
Blunted Heart Rate Response to Regadenoson Predicts Cardiovascular Risk Beyond Quantitative PET Myocardial Blood Flow
Barreto J, Vashist A, Gallegos Kattan C, Stendahl J, Sadeghi M, Sposito A, Miller E, Sinusas A, Feher A, Moura F. Blunted Heart Rate Response to Regadenoson Predicts Cardiovascular Risk Beyond Quantitative PET Myocardial Blood Flow. Journal Of Nuclear Cardiology 2026, 102766. PMID: 42190937, DOI: 10.1016/j.nuclcard.2026.102766.Peer-Reviewed Original ResearchStress myocardial blood flowBlunted heart rate responseIncremental prognostic valueMyocardial flow reserveArea under the receiver-operating characteristic curveHeart rate responsePrognostic valueNet reclassification indexMyocardial blood flowNormal heart rate responseAdenosine A2A receptor agonistA2A receptor agonistReceiver-operating characteristic curveAssociated with higher CV riskBlood flowMedian Follow-UpHigh CV riskMultivariate Cox regressionPredicting cardiovascular riskRate responsePET/CT studiesPrognostic discriminationReceptor agonistsAutonomic dysfunctionClinical characteristicsThe Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis
Przybylski R, Norrish G, Claggett B, Ashley E, Bhole V, Day S, Delle Donne G, Fernandez A, Girolami F, Gray B, Helms A, Ingles J, Kubus P, Lakdawala N, Lampert R, Lin K, Michels M, Miller E, Olivotto I, Owens A, Parikh V, Passantino S, Radulescu C, Rossano J, Russell M, Ryan T, Saberi S, Spentzou G, Stendahl J, Ware J, Weintraub R, Ziolkowska L, Zwetsloot P, Kaski J, Ho C, Abrams D, Investigators F. The Natural History of Massive Left Ventricular Hypertrophy in Pediatric Hypertrophic Cardiomyopathy: A Multiregistry Analysis. Circulation 2026, 153: 1463-1476. PMID: 41993018, DOI: 10.1161/circulationaha.126.078843.Peer-Reviewed Original ResearchConceptsHCM-related mortalityPediatric hypertrophic cardiomyopathyAdverse cardiac eventsHypertrophic cardiomyopathyHeart failureVentricular hypertrophyNatural historyCardiac eventsLt;18 yearsLt;18 years of ageVentricular arrhythmia eventsMassive left ventricular hypertrophyLeft ventricular hypertrophyMajor ventricular arrhythmiasQuarter of patientsCox proportional hazards modelsVentricular wall thicknessSudden cardiac deathTime-to-event analysisHypertrophic cardiomyopathy diagnosisProportional hazards modelYears of ageVentricular arrhythmiasAdverse eventsCardiac death26-A-10988-ACC BLUNTED HEART RATE RESPONSE TO REGADENOSON IS ASSOCIATED WITH HIGH RISK BEYOND PET QUANTITATIVE MYOCARDIAL BLOOD FLOW
Oliveira J, Kattan C, Vashist A, Stendahl J, Sadeghi M, Sposito A, Miller E, Sinusas A, Feher A, Moura F. 26-A-10988-ACC BLUNTED HEART RATE RESPONSE TO REGADENOSON IS ASSOCIATED WITH HIGH RISK BEYOND PET QUANTITATIVE MYOCARDIAL BLOOD FLOW. Journal Of The American College Of Cardiology 2026, 87: a936-a937. DOI: 10.1016/j.jacc.2026.02.2307.Peer-Reviewed Original Research26-A-20816-ACC RISKS IN THE STUDY AND CARE OF PATIENTS WITH PERIPHERAL ARTERY DISEASE: LOWER EXTREMITY CUFF OCCLUSION INCREASES LEFT VENTRICULAR PRESSURE AND REDUCES MYOCARDIAL BLOOD FLOW
Nazari M, Cho S, Tapia C, Jang S, Zohora F, Burns R, Lima M, Depino A, Stendahl J, Jin Y, Meng L, Liu C, Thorn S, Sinusas A. 26-A-20816-ACC RISKS IN THE STUDY AND CARE OF PATIENTS WITH PERIPHERAL ARTERY DISEASE: LOWER EXTREMITY CUFF OCCLUSION INCREASES LEFT VENTRICULAR PRESSURE AND REDUCES MYOCARDIAL BLOOD FLOW. Journal Of The American College Of Cardiology 2026, 87: a1032. DOI: 10.1016/j.jacc.2026.02.2532.Peer-Reviewed Original ResearchDifferences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy
Vissing C, Raja A, Helms A, Saberi S, Owens A, Rossano J, Abrams D, Ingles J, Gray B, Lampert R, Stendahl J, Lakdawala N, Ware J, Parikh V, Michels M, Crotti L, Ryan T, Olivotto I, Day S, Bundgaard H, Claggett B, Ho C. Differences in Disease Trajectory, Comorbidities, and Mortality in Sarcomeric and Nonsarcomeric Hypertrophic Cardiomyopathy. Circulation 2026, 153: 1104-1116. PMID: 41800474, DOI: 10.1161/circulationaha.125.076036.Peer-Reviewed Original ResearchSarcomeric HCMLV systolic dysfunctionAssociated with worse prognosisSystolic dysfunctionHypertrophic cardiomyopathyAtrial fibrillationWorse prognosisVentricular arrhythmiasHighest burdenTime-varying Cox proportional hazards modelsSarcomeric Human Cardiomyopathy RegistryMulticenter longitudinal cohort studyBurden of atrial fibrillationImpact of atrial fibrillationSarcomere gene variantsLongitudinal cohort studyModifiable risk factorsHCM-related mortalitySevere heart failureCox proportional hazards modelsProportion of womenAll-Cause MortalityProportional hazards modelAge-standardizedDisease trajectorySocial Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy
Hafeez N, Claggett B, Owens A, Helms A, Saberi S, Lampert R, Stendahl J, Ashley E, Parikh V, Lakdawala N, Ingles J, Olivotto I, Ho C, Taylor M, Khan S, Day S. Social Determinants of Health and Clinical Outcomes in Hypertrophic Cardiomyopathy. JAMA Cardiology 2026, 11: 165-174. PMID: 41499131, PMCID: PMC12780983, DOI: 10.1001/jamacardio.2025.4869.Peer-Reviewed Original ResearchConceptsSocial determinants of healthSocial deprivation indexMedian household incomeDeterminants of healthPatient's residential addressAdjusted hazard ratiosArea-based indicatorsHousehold incomeSocial determinantsUS adult patientsIndicators of social determinants of healthCohort studyHazard ratioHigher social deprivation indexLow median household incomeComposite outcomeIncome groupsZip code levelProspective cohort studyAssociated with higher riskBody mass indexHigh-income groupsDeprivation indexAmerican Community SurveyDeprived areas
2025
Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy
Saberi S, Kramer C, Oręziak A, Masri A, Barriales-Villa R, Abraham T, Lakdawala N, Wang A, Choudhury L, Rader F, Havakuk O, Stendahl J, Cardim N, Seidler T, Sherrid M, Hegde S, Kwong R, Jerosch-Herold M, Balaratnam G, Kurio G, Fox S, Olivotto I, Owens A. Treatment Response to Mavacamten in Patients With Obstructive Hypertrophic Cardiomyopathy: 96-Week Results From the EXPLORER Cohort of the MAVA–Long-Term Extension Cardiac Magnetic Resonance Imaging Substudy. Circulation 2025, 152: 905-908. PMID: 40982583, PMCID: PMC12991322, DOI: 10.1161/circulationaha.124.071188.Commentaries, Editorials and LettersHealth Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation
Stendahl J, Sen S, Butzner M, Papademetriou E, Potluri R, Liu X, Jacoby D, Freeman J. Health Care Resource Use and Economic Burden in Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy and Atrial Fibrillation. Journal Of The American Heart Association 2025, 14: e038755. PMID: 40847492, PMCID: PMC12553423, DOI: 10.1161/jaha.124.038755.Peer-Reviewed Original ResearchConceptsSymptomatic obstructive hypertrophic cardiomyopathyObstructive hypertrophic cardiomyopathyHealth care resource useCare resource useHealth care costsAtrial fibrillationTotal health care costsIncident AFCare costsHypertrophic cardiomyopathyRetrospective analysisSeptal reduction therapyGreater health care costsRetrospective analysis of claims dataDiagnosis of AFImpact of AFResource useAnalysis of claims dataAdult patientsReduction therapyPatient managementUrgent carePatientsClaims dataCardiomyopathyCurrent management of hypertrophic cardiomyopathy
Sikand N, Stendahl J, Sen S, Lampert R, Day S. Current management of hypertrophic cardiomyopathy. The BMJ 2025, 389: e077274. PMID: 40425241, DOI: 10.1136/bmj-2023-077274.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsOutflow tract gradientObstructive hypertrophic cardiomyopathyHypertrophic cardiomyopathyAtrial fibrillationLeft ventricular outflow tract gradientNon-obstructive hypertrophic cardiomyopathyManagement of hypertrophic cardiomyopathyRisk of sudden deathCardiac sarcomere genesImplantable cardioverter-defibrillator implantationSeptal reduction therapyNon-obstructive diseaseSymptomatic atrial fibrillationCardiac myosin inhibitorLeft ventricular hypertrophySurgical treatment optionsCardioverter-defibrillator implantationAdvanced heart failureStructural heart conditionsArrhythmic riskCardiac transplantationImprove patient outcomesRhythm controlMedical therapyVentricular hypertrophyCorrection to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy
Meisner J, Renberg A, Smith E, Tsan Y, Elder B, Bullard A, Merritt O, Zheng S, Lakdawala N, Owens A, Ryan T, Miller E, Rossano J, Lin K, Claggett B, Ashley E, Michels M, Lampert R, Stendahl J, Abrams D, Semsarian C, Parikh V, Wheeler M, Ingles J, Olivotto I, Day S, Saberi S, Russell M, Previs M, Ho C, Ware J, Helms A. Correction to: Low Penetrance Sarcomere Variants Contribute to Additive Risk in Hypertrophic Cardiomyopathy. Circulation 2025, 151: e762-e762. PMID: 40096296, DOI: 10.1161/cir.0000000000001318.Commentaries, Editorials and Letters
Academic Achievements & Community Involvement
Clinical Care
Overview
John Stendahl, MD, PhD, specializes in cardiovascular imaging and the diagnosis and management of inherited and infiltrative cardiomyopathies. He provides a patient-centered approach to care that is based on the latest scientific findings and diagnostics, and often involves genetic analysis and various types of advanced cardiac imaging.
Dr. Stendahl treats a variety of complex conditions, including hypertrophic, dilated, and arrhythmogenic cardiomyopathies, as well as cardiac amyloid. He performs and interprets various cardiovascular imaging studies, including cardiovascular SPECT, PET, and CT scans. His work includes stress testing and coronary CT for the diagnosis and treatment of coronary artery disease, as well as the latest molecular imaging techniques to evaluate various forms of cardiomyopathy.
In addition to caring for patients, Dr. Stendahl performs clinical and translational research pertaining to hypertrophic cardiomyopathy, heart failure, cardiac transplantation, cardiac devices, and cardiovascular imaging. This includes clinical trials of the latest medications to treat cardiomyopathies, as well as translational work focused on development and discovery.
Clinical Specialties
Cardiovascular Medicine
Fact Sheets
Hypertrophic Cardiomyopathy
Learn More on Yale MedicineCT Scan for Coronary Artery Disease
Learn More on Yale MedicineChronic Total Occlusion (CTO)
Learn More on Yale MedicinePulmonary Edema
Learn More on Yale Medicine
Board Certifications
Nuclear Cardiology
- Certification Organization
- Certification Board of Nuclear Cardiology
- Original Certification Date
- 2020
Cardiovascular Disease
- Certification Organization
- AB of Internal Medicine
- Original Certification Date
- 2019
Yale Medicine News
News
News
- June 24, 2026
YBII Pilot Grant Awardees - Spring 2026
- January 16, 2024
Yale's Cardiac Imaging Center Revolutionizes Translational Research
- May 17, 2023
Feher selected for ASNC leadership development program
- April 24, 2023Source: HealthCentral
Top HCM Fears and How to Conquer Them
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.